XML 38 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1
Janssen Collaboration Agreement (Details) - Collaborative Arrangement, Product [Member] - USD ($)
3 Months Ended
Sep. 30, 2017
Jun. 30, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaborative arrangement, percentage of development costs incurred   20.00%
Janssen Biotech, Inc. [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Collaborative arrangement, percentage of development costs incurred   80.00%
Janssen Biotech, Inc. [Member] | Scenario, Forecast [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Nonrefundable upfront payment $ 50,000,000  
Revenue recognition, milestone method, revenue recognized $ 615,000,000  
Collaboration agreement, detail capital required for commercial launch, percent (up to) 30.00%  
First Opt-in [Member] | Janssen Biotech, Inc. [Member] | Scenario, Forecast [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Future opt-in payment eligible to receive under collaboration arrangement $ 125,000,000  
Second Opt-in [Member] | Janssen Biotech, Inc. [Member] | Scenario, Forecast [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Future opt-in payment eligible to receive under collaboration arrangement $ 200,000,000